BY TANYA KWIEZ August 9, 2021
Biome Eczema™, the latest precision probiotic from Activated Probiotics, contains a specific probiotic strain that has been shown to help relieve the symptoms of mild eczema in various clinical trials. As the number of people suffering from eczema continues to climb, Biome Eczema™ is a new evidence-based tool that can help to provide relief for sufferers of mild eczema and improve their quality of life.
Over 1 million Australians suffer from eczema, a chronic inflammatory skin condition that is diagnosed in up to 1 in 3 Australian children and typically within the first six months of life (1).
Eczema is characterised by dry, red, scaly skin that is extremely itchy. It can significantly reduce a person’s quality of life, with painful skin and poor sleep being common side effects. While some children grow out of it, it still affects approximately 5% of adults.
As eczema cannot be cured and can only be managed, it is vital for health research to investigate new treatments that can improve symptoms and, most importantly, improve quality of life for people suffering with eczema.
The development of eczema is complex, but some answers can be found when we look at an individual’s immune system and their gut microbiome.
Atopic dermatitis is the most common form of eczema and is thought to be caused by increased immune sensitivity and allergic reactions in the skin. These allergic reactions are often behind the development of dry, red, itchy eczema lesions that many people are familiar with.
Immune sensitivity and the likelihood of developing allergic conditions like atopic dermatitis is largely determined in the first few years of life. This is an important time for the development of a healthy immune system. When immune system development is disturbed, it can create a hypersensitive immune system which begins to react to allergens. In some people, this manifests as eczema.
The development of the immune system is now known to be heavily influenced by the health of the gut microbiome. Microbes in our gut communicate with our immune cells lying just below the surface of the gut through different signals that pass through the gut wall.
A well-balanced and healthy gut microbiome helps to train our immune system to fight off infections while also teaching it to remain calm in the presence of foods and other potential allergens, like pollen.
Therefore, an unhealthy gut microbiome is thought to contribute to the prevalence and persistence of allergic diseases, such as atopic dermatitis.
Indeed, scientific research has demonstrated that the gut microbiome contributes to the development and severity of eczema through its impact on the immune system.
Studies have observed a consistent association between an unhealthy gut microbiota (gut dysbiosis) and atopic eczema in infants. Experts suggest that gut dysbiosis in the infant microbiome triggers abnormal immune development in early childhood and ultimately creates a hypersensitive immune system.
Emerging evidence is now indicating that probiotics which target the gut microbiome are a promising solution for the treatment of eczema, specifically atopic dermatitis.
Due to their ability to interact with the immune system in the gut, specific strains of probiotic bacteria have been found to improve immune system function and reduce the immune responses that are creating eczema in the skin.
With the publication of several clinical trials, specific probiotic strains are now emerging as an important part of eczema management protocols.
A randomised, placebo-controlled trial in 2012 found that Lactobacillus salivarius LS01 helped to reduce the symptoms of mild eczema in 38 patients after 4 months of treatment when compared to placebo. Those taking the probiotic strains had a 52% reduction in symptom severity, and their quality of life was found to improve by 55%. Another study in 2014 found that this same probiotic significantly improved symptoms of mild eczema, including itch, after 4 weeks in a group of 43 children.
Biome Eczema™ contains the clinically trialled probiotic strain Lactobacillus salivarius LS01. This strain reduces the symptoms of mild eczema via the gut-skin axis and relives itchy skin associated with mild eczema. Data on Lactobacillus salivarius LS01 shows promising potential in not only managing symptoms but improving the quality of life for children and adults affected by AD.
1. Martin PE, Koplin JJ, Eckert JK, Lowe AJ, Ponsonby AL, Osborne NJ, Gurrin LC, Robinson MN, Hill DJ, Tang ML, Dharmage SC, Allen KJ, (2013). HealthNuts Study Investigators. The prevalence and socio-demographic risk factors of clinical eczema in infancy: a population-based observational study. Clin Exp Allergy;43(6):642-51.
2. Biedermann T, Skabytska Y, Kaesler, Volz T, (2015). Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation, Frontiers in Immunology; 6:353.
3. Lee SY, Lee E, Park YM, Hong SJ, (2018). Microbiome in the Gut-Skin Axis in Atopic Dermatitis. Allergy Asthma Immunol Res;10(4):354-362.
4. Reddel S, Del Chierico F, Quagliariello A et al, (2019). Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture. Sci Rep 9, 4996.
5. Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S, (2011). Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol;24(4):1037-48.
To help reduce the symptoms of mild eczema